BioSpace News Archive

IQVIA Acquires Remaining Interest in Q 2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance

Palantir Technologies (NYSE:PLTR) today issued additional details about the Palantir Foundry capabilities it will be highlighting in its Life Sciences demo at “Double Click” on Wednesday, April 14, 2021, at 11:00am ET.

Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced the signing of an agreement with Aytu BioPharma

KAHR adds two preclinical products, DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein, to its pipeline

G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that the Company will host a virtual COSELA Kickoff Analyst and Investor Summit on Friday, April 9, 2021 from 9:00 a.m. to 11:00 a.m. EDT.

Broncus Medical , Inc., developer of diagnostic and therapeutic technology for a variety of lung diseases, today announced publication of results from the VAPORIZE study in the current issue of Respiration. The feasibility study reported on the use of bronchoscopic thermal vapor ablation (BTVA) in ablating lung tumors.

LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCEs) to transform cancer therapy, today announced that Karen J. Wilson has been appointed to its Board of Directors and as chair of its Audit Committee.

StageZero Life Sciences, Ltd is pleased to announce that effective March 31, 2021 is has entered into a letter of intent to purchase substantially all of the business of Health Clinics Limited and of Health Clinics USA Corp.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB.

Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry research and development veteran, William Kennedy, M.D., as Senior Vice President, Clinical, effective Thursday, April 1.